The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women-A Pilot Randomized Clinical Trial - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Nov 3;16(21):3775.
doi: 10.3390/nu16213775.

The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women-A Pilot Randomized Clinical Trial

Araceli Montoya-Estrada  1 , Aline Yunuen García-Cortés  2 , José Romo-Yañez  1 , Guillermo F Ortiz-Luna  3 , Arturo Arellano-Eguiluz  3 , Aurora Belmont-Gómez  4 , Vivian Lopéz-Ugalde  4 , Guadalupe León-Reyes  5 , Arturo Flores-Pliego  6 , Aurora Espejel-Nuñez  6 , Juan Mario Solis-Paredes  7 , Enrique Reyes-Muñoz  8
Affiliations
Randomized Controlled Trial

The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women-A Pilot Randomized Clinical Trial

Araceli Montoya-Estrada et al. Nutrients. .

Abstract

In postmenopausal women, due to endocrine changes, there is an increase in oxidative stress (OS) that predisposes them to cardiovascular and metabolic alterations. Sixty-one percent of women in this stage require a primary therapeutic strategy to decrease OS. This study aimed to evaluate the effect of resveratrol and vitamin C on OS in postmenopausal women. A randomized, double-blind clinical trial was carried out. Forty-six postmenopausal women with insulin resistance (HOMA-IR > 2.5) were included and divided into three treatment groups: group A: resveratrol, n = 13; group B: resveratrol + vitamin C, n = 15; and group C: vitamin C, n = 14. Between before and after the antioxidants, group B showed a decrease of 33% in lipohydroperoxides (p = 0.02), and malondialdehyde (MDA) decreased by 26% (p = 0.0007), 32% (p = 0.0001), and 38% (p = 0.0001) in groups A-C, respectively. For protein damage, group B is the most representative, with a decrease of 39% (p = 0.0001). For total antioxidant capacity (TAC), there were significant increases of 30% and 28% in groups B and C, respectively. For HOMA-IR, there were no significant differences among the study groups. Supplementation with this combination of antioxidants significantly decreases markers of OS in postmenopausal women. In addition, it increases TAC by up to 30%.

Keywords: antioxidants; insulin resistance; malondialdehyde; oxidative stress; polyphenol; postmenopause; protein damage; total antioxidant capacity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the participants in the study.
Figure 2
Figure 2
LHP concentration before and after treatment in postmenopausal women with insulin resistance. Resveratrol group, n = 13; resveratrol and vitamin C group, n = 15; and vitamin C group, n = 14. The results obtained were analyzed using Student’s “t”. Data are presented as mean ± standard deviation. * p < 0.05.
Figure 3
Figure 3
MDA concentrations before and after treatment in postmenopausal women with insulin resistance. Resveratrol group, n = 13; resveratrol and vitamin C group, n = 15; and vitamin C group, n = 14. The results obtained were analyzed using Student’s “t”. Data are presented as mean ± standard deviation. ** p < 0.01, *** p < 0.001.
Figure 4
Figure 4
Protein carbonylation concentration before and after treatment in postmenopausal women with insulin resistance. Resveratrol group, n = 13; resveratrol and vitamin C group, n = 15; and vitamin C group, n = 14. The results obtained were analyzed using Student’s “t”. Data are presented as mean ± standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 5
Figure 5
Total antioxidant capacity before and after treatment in postmenopausal women with insulin resistance. Resveratrol group, n = 13; resveratrol and vitamin C group, n = 15; and vitamin C group, n = 14. The results obtained were analyzed using Student’s “t” test. Data are presented as mean ± standard deviation. * p < 0.05.
Figure 6
Figure 6
HOMA-IR before and after treatment in postmenopausal women with insulin resistance. Resveratrol group, n = 13; resveratrol and vitamin C group, n = 15; and vitamin C group, n = 14. The results obtained were analyzed using Student’s “t”. Data are presented as mean ± standard deviation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Minkin M.J. Menopause: Hormones, Lifestyle, and Optimizing Aging. Obstet. Gynecol. Clin. N. Am. 2019;46:501–514. doi: 10.1016/j.ogc.2019.04.008. - DOI - PubMed
    1. Delamater L., Santoro N. Management of the Perimenopause. Clin. Obstet. Gynecol. 2018;61:419–432. doi: 10.1097/GRF.0000000000000389. - DOI - PMC - PubMed
    1. Troìa L., Martone S., Morgante G., Luisi S. Management of perimenopause disorders: Hormonal treatment. Gynecol. Endocrinol. 2021;37:195–200. doi: 10.1080/09513590.2020.1852544. - DOI - PubMed
    1. Society N.A.M. Menopause Practice: A Clinician’s Guide. North American Menopause Society; Pepper Pike, OH, USA: 2019.
    1. Mumusoglu S., Yildiz B.O. Metabolic Syndrome During Menopause. Curr. Vasc. Pharmacol. 2019;17:595–603. doi: 10.2174/1570161116666180904094149. - DOI - PubMed

Publication types

Grants and funding

This research was funded by Direccion General de Politicas en Investigación en Salud (DGPIS), grant number FPIS2023-INPER-4245, and Instituto Nacional de perinatología “Isidro Espinosa de los Reyes”, grant numbers 3210-10209-01-574-17 and 2023-1-37.

LinkOut - more resources